CA1210328A - Method and composition for the evaluation of phagocytic response - Google Patents
Method and composition for the evaluation of phagocytic responseInfo
- Publication number
- CA1210328A CA1210328A CA000441805A CA441805A CA1210328A CA 1210328 A CA1210328 A CA 1210328A CA 000441805 A CA000441805 A CA 000441805A CA 441805 A CA441805 A CA 441805A CA 1210328 A CA1210328 A CA 1210328A
- Authority
- CA
- Canada
- Prior art keywords
- phagocytic
- cells
- particles
- luminol
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Method and Composition for the Evaluation of Phagocytic Response Abstract Methods and compositions for measuring phagocytosis and biochemical activity of phagocytic cells are described. A sample of blood cells is taken from an organism. The phagocytic activity of the blood phago-cytes is estimated by the direct addition of a parti-culate material comprising zymosan particles adsorbed with protein having a luminescent chemical admixed therewith. Alternatively, phagocytic cells from said sample are purified and mixed with zymosan or a polymeric particle chemically coated with protein and luminescent chemical. When the phagocytic cells are mixed with either of these compositions, the cells engulf the particles thus causing the activation of the cells' biochemical mechanisms. Oxygen intermediates result from this mechanism causing a reaction with the luminescent chemical resulting in the production of light. This light is measured on a luminometer and based on the rate of light production and the maximum produced, the phagocytic activity of said cells is measured.
Description
~l2~03~
Description Method and Composition for the Evaluation of Phagocytic Response Technical Field The field of art to which this invention pertains is assay methods of measuring the ability of an organism to resist infection, compositions useful therefor, and methods of making such compositions.
Background Art The observation that certain phagocytic cells found in the blood and in organs such as the lung generate light as a result of the ~hysical ingestion of particles such as bacteria or non-living compositions has been published over the years in the scientific literature.
These observations are based on specific cells found in the blood or organs which are known to serve a critical function of seeXing out, phagocytosing (engulf-ing) and killing such particles such as bacteria through complex chemical mechanisms. These cells may also seek out and remove non-infectious agents such as airboxnP particulate pollutants~ Part of this cellular chemical mechanism includes the production of relatively high energy oxygen intermediates. The cell will pro-duce the~e chemicals when stimulated to phagocytize.
These high energy oxygen intermediates will decay to lower energy levels and in the process light will be generated. ~lthough ~hese low levels of light are detectable using instruments such as liquid scintilla-tion spectrometers, this is a very cumbersome techniaue EP-1550 ~
, ~2~0~æ~
which does not permit rapid analysis of a large number of samples or samples ~ith a large number of variables to b~ investiyated. And, while this phenomenon has been known for some time, little advantage has been taken of it due to the limitations described above along with nonavailability of relatively stable reagents.
Disclosure of Invention The present invention is directed to a method of measuring the phagocytic response of various phagocytic cells. 5uch method takes advantage of the process of phagocytosis used by an organism to resist infection or to remove particulate matter from the lungs, etc. A
sample of blood-derived or organ-derived phagocytic cells is taken from a human or another animal and a particle-containing material added thereto which is engulfed by the phagocytic cells. The cells respond to the particle-containing material and generate oxygen intermediates which in turn, react with a chemical in the particle-containiny material. This reaction generates light as a result. This light so produced is detected and measured.
Another aspect of the invention includes one such particle-containing reagent adapted to being phago-cytized by the cells and comprises polymeric beads coated with proteins to which a luminescent chemical such as 5-amino-2,3,dihydro-1, 4-phthalazinedione (luminol) is bonded thereto.
Another aspect of the invention includes another such particle-containing reagent adapted to beiny phagocytized by ~he cells and comprises polysaccharide particles derived from yeast cell walls (zymosan) ~2~32~
adsorbed with proteins to which a luminescent chemical (luminol~ is admixed.
Another aspec~ of the invention includes a method of making the coated, particulate, polymeric beads according to the present invention. The polymeric beads, about 2 to about 9 microns in diameter are coated with a protein and luminescent chemical. The luminescent chemical can be coated on the protein or admixed with the protein and the two applied to the polymeric beads together. The resultant particles are washed, resuspended to a final concentration and lyophilized.
Another aspect of the invention includes a method of making the coated zymosan particles useful according to the present invention. The zymssan particles are coated with a protein. Luminol is mixed with the coated particles and th`e resultant material is lyo-philized into a stable, homogeneous product.
The foregoing, and other features and advantages of the present inventionJ will become more apparent from the following description and the accompanying dxawings.
Brief Description of the Drawings Fig. 1 shows a typical response of diluted whole blood chemiluminescent assay using zymosan based reagent.
Fig, 2 shows a typical response of isolat~d neutrophils-assay using zymosan based reagent.
210~
Fig. 3 shows a typical response of isolated neutrophils-assay using polymeric bead based reagent.
Fig. 4 shows a typical response of diluted whole blood chemiluminescent assay using zymosan based reagent.
Fig. 5 shows ~ typical response of isolated neutrophils-assay using zymosan based reagent.
Fig. 6 shows a typical respon~e of isolated neutrophils-assay using polymeric bead based reagent.
Best Mode for Carrying Out the Invention While any particulate ~ased material compatible with the phagocytic cell system may be used, organically-derived polymeric material and parti-cularly polyacrylamides (for example, Bio-Rad~
particles, Richmond, California) and particulate zymosan have been found to be particularly suitable.
In order for this system to function properly, it is necessary to coat protein onto the particulate material. m is coating may be accomplished by actual chemical linkage of the protein to the particle or by simple electrostatic adsorption. Any suitable pro-tein or mixture of proteins may be used to thus sensitize the beads. Suitable proteins include puri-2S fied human immunoglobulin G or human or animal serum.
Next, the luminescent chemical is either chemicallyor by ad~orption, coated on or admixed with the pro-tein coated particles. While any luminescent chemical that reacts with oxygen intermediates directly or indirectly generating light can be us d, luminol (e.g.
v ~2~3Z
.
available from Eastman Organics, Rochester, New York) has been found to be particularly suitable. If the polymer bead is used, the luminol is dissolved in an aqueous buffered solution, and preferably reacted to form a reactive azo-intermediate. me azo-intermediate is then reacted with the protein coated polymeric particles. This results in an azoluminol-protein adduct as well as elec~rostatically bound luminol-polyacrylamide. m e resulting particles are washed, resuspended to a final concentration, filled into vials and lyophilized. The material derived from this process yields a stable, homogeneous product.
The luminol can also simply be admixed with a suspension of zymosan particles previously coated with a suitable protein. The resulting admixture is filled into vials and lyophilized. Tha material derived from this process yields a stable, homogeneous product.
The lyophiliæed product described above is, after reconstitution with water, ready to use in the assay method.
For the assay method using polymeric particles, 1,000,000 to about 2,000,000 polyacrylamide particles in 50 microliters of buffer are mixed with about 200,000 purified phagocytic cells in 100 microliters of bufer. Two exemplary assay methods used in con-junction with the zymosan particles are: (1) whole blood is diluted 1:3 (one part anticoagulated blood plus t~o parts buffer). Fifty microliter~ of this dilution are mixed with 200 microliters of the coated 21~
zymosan containing luminol. Each milliliter of zymosan mixture contains approximately 50,0Q0,000 particles; and ~2) Fifty microliters of zymosan suspension is mixed with 100 microliters buffer con-taining approximately 200,000 purified phagocytic cells.
The light generated from these mixtures is monitored periodically over time and measures the phagocytic and biochemical activity of the phagocytic cell pre-paration. Cells which may be evaluated by this tech-nique include neutrophils, monocytes and alveolar macrophages~ The first two of these cell types are obtained from whole blood placed on a density gradient such as Ficoll~ - Hypaque~ and centrifuged. These cells band in the gradient and are thus purified.
Macrophages are obtained from lung washings and do not require purification. In the following examples, neutrophils are used.
Example 1 200 mg of the ~bove-described polyacrylamide beads having a 2-9 micron diameter are suspended in 20 ml of water. To this suspension, 10 mg of human immunoglobulin G (IgG) are added. The protein bead suspension is gently mixed and then chilled to 2C-8C. 40 mg o~ l~ethyl-3,3-dimethyl aminopropyl carbodiimide hydrochloride is 2S added. Six hours later, lS0 mg of glycine is added.
The mi~ture is stirred overnight at 2C-8~C. The next day, the suspension iæ washed by centrifugation with ph~sphate buffered saline, 1.4 M sodium chloride in phosphate buffered saline and finally 0.005 M phosphate ~210~
buffer. The beads are centrifuged again and resuspended in 8.5 ml of 0.5 M pH 8.5 borate buffer.
A diazonium salt of luminol is prepared by suspend-i~g 200 mg luminol in 20 ml 2.4 N HCl The mixture is S chilled on ice. 2.0 ml 100 mg per ml sodium nitrite is added, mixed, followed rapidly by the addition of chilled buffer, 50 ml 0.5 m pH 8.5. The pH is observed and adjusted with lO N sodium hydroxide to pH 7.1 +0.1.
14 ml of the diazonium salt of luminol is then added to the 8.5 ml of resuspended beads described above and the pH adjusted to pH 8.5. The suspension is mixed for three hours in the dark at 2~C-8C.
The diazotized bead suspension is then dialyzed against several changes of 0.2 M pH 8.0 borate buffer at 2C-8C. Dialysis proceeds for at least 24 hours.
The beads are then washed by centrifugation using 0.2 M pH 8.0 borate buffer until the supernatant has less than 1.0% of the initial light output of the total suspension, i.e. greater than 99% of luminol associated with the beads.
The beads are then centrifuged once again. The beads are resuspended in phosphate buffered saline. T~e bead concentration is adjusted to approximately 50,000,000 beads per milliliter as determined with a hemocytometer.
The suspension is then filled into vials in l.0 ml por-tions and lyophilized to less than 5.0% residual moisture as determined by Karl Fisher titration.
To use in the phagocytic assay, a vial is recon-stituted by the addition of l.0 ml purified water.
Example 2 Zymosan A (Sigma Chemical Co., St. Louis, Missouri) is suspended in phosphate buffered saline to a concentra tion of 24 mg per ml. To this suspension is added an equal volume of 50% normal rabbit serum diluted in phos-phate buffered saline, The suspension is incubated for one hour at 37C in a shaking water bath. The suspension is then centri uged, the supernatant discarded and the thus treated Zymosan A (pellet) resuspended in a small volume of phosphate buffered saline. The suspension is then drawn through a syringe needle (18-2Ç gauge) to homogenize the suspension. Finally sufficient phosphate buffered saline is added to four times the original volume of suspension resulting in an approximate 6 mg per ml suspension. This suspension is then passed through a glass wool plug to entrap any remaining large clumps of zymosan.
A stock solution of luminol is prepared by dissolv-ing it in 0.01 N sodium hydroxide. An aliquot of this stock solution is then added to a solution containing 20% fetal calf serum in phosphate buffered saline result-ing in a luminol concentration of 14.4 micrograms per ml.
To one volume of zymosan suspension is added one volume of luminol-fetal calf serum solution. The result-ing suspension is mixed, filled into vials in 2.0 mlportions and lyophilized to less than 5% residual moisture as determined by Karl Fisher titration.
To use in the phagocytosis assay, a vial is recon-stituted with 2.0 ml purified water~
~2~32 !3 Example 3 Several children previously diagnosed as having chronic granulomatous disease (CGD) were e~amined using the reagents and assay method described above.
This disease was selected since the dysfunction is understood. CGD is caused by the absence of certain enzymes found in phagocytic cells of the blood.
Although the phagocytic cells are capahle of engulfing bacteria (particles), the cells are unable to inactivate or kill the bacteria since the phagocytic cells lack the ability to generate high energy oxygen intermediates.
As such, they cannot cause the oxidation of luminol so engulfed by the cells, hence no detectable light response is observed. Clinically, these children typi-call~ present or manifest this decrease as a severereduction in their ability to resist infectionO See Figures 1-3 for typical response. When these children were tested along with apparently healthy control sub-jects, they produced no light from luminol oxidation, although they engulfed particles as effectively as the controls.
Example 4 A yroup of children previously diagnosed as haviny asthma were examined as related to their phagocytic/
biochemical response of phagocytic cells. Approximately half the children were receiving tharapeutic doses of theophylline; the remaining children had not been placed on this medication. Theophylline is thought to have an effect on cyclic adenosine monophosphate (c-AMP) which is known to exert regulatory control over certain biochemical actions o_ phagocytic cells. See Figures 3~
4-6. The children receiving theophylline generally demonstrated reduced le~els of oxygen intermediate pro-duction as quantitated by reduced luminol oxidation and light production.
Such methods as described have particular utility for the quantification of infection resistance in terms of phagocyte activity. However, such process also has application in medical diagnosis, environmental immunotoxicology, pharmacology, such as for monitoring toxicity of chemotherapy and radiation therapy patients, as examples. It can be used for the evaluation of immunocompetency, certain hlood serum protein defects~
etc. As a research tool, it can be used to test pharmaceutical compounds and their effect on phagocytes, effects of pollutants on phagocytic cells and the effect of toxic compounds on animals and humans.
Although this invention has been described with respect to detailed embodiments thereof, it will be understood by tho~e skilled in the art that various changes in form and detail thereof may be made without departing from the spirit and scope of the claimed invention.
Description Method and Composition for the Evaluation of Phagocytic Response Technical Field The field of art to which this invention pertains is assay methods of measuring the ability of an organism to resist infection, compositions useful therefor, and methods of making such compositions.
Background Art The observation that certain phagocytic cells found in the blood and in organs such as the lung generate light as a result of the ~hysical ingestion of particles such as bacteria or non-living compositions has been published over the years in the scientific literature.
These observations are based on specific cells found in the blood or organs which are known to serve a critical function of seeXing out, phagocytosing (engulf-ing) and killing such particles such as bacteria through complex chemical mechanisms. These cells may also seek out and remove non-infectious agents such as airboxnP particulate pollutants~ Part of this cellular chemical mechanism includes the production of relatively high energy oxygen intermediates. The cell will pro-duce the~e chemicals when stimulated to phagocytize.
These high energy oxygen intermediates will decay to lower energy levels and in the process light will be generated. ~lthough ~hese low levels of light are detectable using instruments such as liquid scintilla-tion spectrometers, this is a very cumbersome techniaue EP-1550 ~
, ~2~0~æ~
which does not permit rapid analysis of a large number of samples or samples ~ith a large number of variables to b~ investiyated. And, while this phenomenon has been known for some time, little advantage has been taken of it due to the limitations described above along with nonavailability of relatively stable reagents.
Disclosure of Invention The present invention is directed to a method of measuring the phagocytic response of various phagocytic cells. 5uch method takes advantage of the process of phagocytosis used by an organism to resist infection or to remove particulate matter from the lungs, etc. A
sample of blood-derived or organ-derived phagocytic cells is taken from a human or another animal and a particle-containing material added thereto which is engulfed by the phagocytic cells. The cells respond to the particle-containing material and generate oxygen intermediates which in turn, react with a chemical in the particle-containiny material. This reaction generates light as a result. This light so produced is detected and measured.
Another aspect of the invention includes one such particle-containing reagent adapted to being phago-cytized by the cells and comprises polymeric beads coated with proteins to which a luminescent chemical such as 5-amino-2,3,dihydro-1, 4-phthalazinedione (luminol) is bonded thereto.
Another aspect of the invention includes another such particle-containing reagent adapted to beiny phagocytized by ~he cells and comprises polysaccharide particles derived from yeast cell walls (zymosan) ~2~32~
adsorbed with proteins to which a luminescent chemical (luminol~ is admixed.
Another aspec~ of the invention includes a method of making the coated, particulate, polymeric beads according to the present invention. The polymeric beads, about 2 to about 9 microns in diameter are coated with a protein and luminescent chemical. The luminescent chemical can be coated on the protein or admixed with the protein and the two applied to the polymeric beads together. The resultant particles are washed, resuspended to a final concentration and lyophilized.
Another aspect of the invention includes a method of making the coated zymosan particles useful according to the present invention. The zymssan particles are coated with a protein. Luminol is mixed with the coated particles and th`e resultant material is lyo-philized into a stable, homogeneous product.
The foregoing, and other features and advantages of the present inventionJ will become more apparent from the following description and the accompanying dxawings.
Brief Description of the Drawings Fig. 1 shows a typical response of diluted whole blood chemiluminescent assay using zymosan based reagent.
Fig, 2 shows a typical response of isolat~d neutrophils-assay using zymosan based reagent.
210~
Fig. 3 shows a typical response of isolated neutrophils-assay using polymeric bead based reagent.
Fig. 4 shows a typical response of diluted whole blood chemiluminescent assay using zymosan based reagent.
Fig. 5 shows ~ typical response of isolated neutrophils-assay using zymosan based reagent.
Fig. 6 shows a typical respon~e of isolated neutrophils-assay using polymeric bead based reagent.
Best Mode for Carrying Out the Invention While any particulate ~ased material compatible with the phagocytic cell system may be used, organically-derived polymeric material and parti-cularly polyacrylamides (for example, Bio-Rad~
particles, Richmond, California) and particulate zymosan have been found to be particularly suitable.
In order for this system to function properly, it is necessary to coat protein onto the particulate material. m is coating may be accomplished by actual chemical linkage of the protein to the particle or by simple electrostatic adsorption. Any suitable pro-tein or mixture of proteins may be used to thus sensitize the beads. Suitable proteins include puri-2S fied human immunoglobulin G or human or animal serum.
Next, the luminescent chemical is either chemicallyor by ad~orption, coated on or admixed with the pro-tein coated particles. While any luminescent chemical that reacts with oxygen intermediates directly or indirectly generating light can be us d, luminol (e.g.
v ~2~3Z
.
available from Eastman Organics, Rochester, New York) has been found to be particularly suitable. If the polymer bead is used, the luminol is dissolved in an aqueous buffered solution, and preferably reacted to form a reactive azo-intermediate. me azo-intermediate is then reacted with the protein coated polymeric particles. This results in an azoluminol-protein adduct as well as elec~rostatically bound luminol-polyacrylamide. m e resulting particles are washed, resuspended to a final concentration, filled into vials and lyophilized. The material derived from this process yields a stable, homogeneous product.
The luminol can also simply be admixed with a suspension of zymosan particles previously coated with a suitable protein. The resulting admixture is filled into vials and lyophilized. Tha material derived from this process yields a stable, homogeneous product.
The lyophiliæed product described above is, after reconstitution with water, ready to use in the assay method.
For the assay method using polymeric particles, 1,000,000 to about 2,000,000 polyacrylamide particles in 50 microliters of buffer are mixed with about 200,000 purified phagocytic cells in 100 microliters of bufer. Two exemplary assay methods used in con-junction with the zymosan particles are: (1) whole blood is diluted 1:3 (one part anticoagulated blood plus t~o parts buffer). Fifty microliter~ of this dilution are mixed with 200 microliters of the coated 21~
zymosan containing luminol. Each milliliter of zymosan mixture contains approximately 50,0Q0,000 particles; and ~2) Fifty microliters of zymosan suspension is mixed with 100 microliters buffer con-taining approximately 200,000 purified phagocytic cells.
The light generated from these mixtures is monitored periodically over time and measures the phagocytic and biochemical activity of the phagocytic cell pre-paration. Cells which may be evaluated by this tech-nique include neutrophils, monocytes and alveolar macrophages~ The first two of these cell types are obtained from whole blood placed on a density gradient such as Ficoll~ - Hypaque~ and centrifuged. These cells band in the gradient and are thus purified.
Macrophages are obtained from lung washings and do not require purification. In the following examples, neutrophils are used.
Example 1 200 mg of the ~bove-described polyacrylamide beads having a 2-9 micron diameter are suspended in 20 ml of water. To this suspension, 10 mg of human immunoglobulin G (IgG) are added. The protein bead suspension is gently mixed and then chilled to 2C-8C. 40 mg o~ l~ethyl-3,3-dimethyl aminopropyl carbodiimide hydrochloride is 2S added. Six hours later, lS0 mg of glycine is added.
The mi~ture is stirred overnight at 2C-8~C. The next day, the suspension iæ washed by centrifugation with ph~sphate buffered saline, 1.4 M sodium chloride in phosphate buffered saline and finally 0.005 M phosphate ~210~
buffer. The beads are centrifuged again and resuspended in 8.5 ml of 0.5 M pH 8.5 borate buffer.
A diazonium salt of luminol is prepared by suspend-i~g 200 mg luminol in 20 ml 2.4 N HCl The mixture is S chilled on ice. 2.0 ml 100 mg per ml sodium nitrite is added, mixed, followed rapidly by the addition of chilled buffer, 50 ml 0.5 m pH 8.5. The pH is observed and adjusted with lO N sodium hydroxide to pH 7.1 +0.1.
14 ml of the diazonium salt of luminol is then added to the 8.5 ml of resuspended beads described above and the pH adjusted to pH 8.5. The suspension is mixed for three hours in the dark at 2~C-8C.
The diazotized bead suspension is then dialyzed against several changes of 0.2 M pH 8.0 borate buffer at 2C-8C. Dialysis proceeds for at least 24 hours.
The beads are then washed by centrifugation using 0.2 M pH 8.0 borate buffer until the supernatant has less than 1.0% of the initial light output of the total suspension, i.e. greater than 99% of luminol associated with the beads.
The beads are then centrifuged once again. The beads are resuspended in phosphate buffered saline. T~e bead concentration is adjusted to approximately 50,000,000 beads per milliliter as determined with a hemocytometer.
The suspension is then filled into vials in l.0 ml por-tions and lyophilized to less than 5.0% residual moisture as determined by Karl Fisher titration.
To use in the phagocytic assay, a vial is recon-stituted by the addition of l.0 ml purified water.
Example 2 Zymosan A (Sigma Chemical Co., St. Louis, Missouri) is suspended in phosphate buffered saline to a concentra tion of 24 mg per ml. To this suspension is added an equal volume of 50% normal rabbit serum diluted in phos-phate buffered saline, The suspension is incubated for one hour at 37C in a shaking water bath. The suspension is then centri uged, the supernatant discarded and the thus treated Zymosan A (pellet) resuspended in a small volume of phosphate buffered saline. The suspension is then drawn through a syringe needle (18-2Ç gauge) to homogenize the suspension. Finally sufficient phosphate buffered saline is added to four times the original volume of suspension resulting in an approximate 6 mg per ml suspension. This suspension is then passed through a glass wool plug to entrap any remaining large clumps of zymosan.
A stock solution of luminol is prepared by dissolv-ing it in 0.01 N sodium hydroxide. An aliquot of this stock solution is then added to a solution containing 20% fetal calf serum in phosphate buffered saline result-ing in a luminol concentration of 14.4 micrograms per ml.
To one volume of zymosan suspension is added one volume of luminol-fetal calf serum solution. The result-ing suspension is mixed, filled into vials in 2.0 mlportions and lyophilized to less than 5% residual moisture as determined by Karl Fisher titration.
To use in the phagocytosis assay, a vial is recon-stituted with 2.0 ml purified water~
~2~32 !3 Example 3 Several children previously diagnosed as having chronic granulomatous disease (CGD) were e~amined using the reagents and assay method described above.
This disease was selected since the dysfunction is understood. CGD is caused by the absence of certain enzymes found in phagocytic cells of the blood.
Although the phagocytic cells are capahle of engulfing bacteria (particles), the cells are unable to inactivate or kill the bacteria since the phagocytic cells lack the ability to generate high energy oxygen intermediates.
As such, they cannot cause the oxidation of luminol so engulfed by the cells, hence no detectable light response is observed. Clinically, these children typi-call~ present or manifest this decrease as a severereduction in their ability to resist infectionO See Figures 1-3 for typical response. When these children were tested along with apparently healthy control sub-jects, they produced no light from luminol oxidation, although they engulfed particles as effectively as the controls.
Example 4 A yroup of children previously diagnosed as haviny asthma were examined as related to their phagocytic/
biochemical response of phagocytic cells. Approximately half the children were receiving tharapeutic doses of theophylline; the remaining children had not been placed on this medication. Theophylline is thought to have an effect on cyclic adenosine monophosphate (c-AMP) which is known to exert regulatory control over certain biochemical actions o_ phagocytic cells. See Figures 3~
4-6. The children receiving theophylline generally demonstrated reduced le~els of oxygen intermediate pro-duction as quantitated by reduced luminol oxidation and light production.
Such methods as described have particular utility for the quantification of infection resistance in terms of phagocyte activity. However, such process also has application in medical diagnosis, environmental immunotoxicology, pharmacology, such as for monitoring toxicity of chemotherapy and radiation therapy patients, as examples. It can be used for the evaluation of immunocompetency, certain hlood serum protein defects~
etc. As a research tool, it can be used to test pharmaceutical compounds and their effect on phagocytes, effects of pollutants on phagocytic cells and the effect of toxic compounds on animals and humans.
Although this invention has been described with respect to detailed embodiments thereof, it will be understood by tho~e skilled in the art that various changes in form and detail thereof may be made without departing from the spirit and scope of the claimed invention.
Claims (12)
1. A method of measuring the ability of an organism to resist infection comprising taking a sample of blood from the organism, separating the phagocytic cells from the blood, adding to the phagocytic cells par-ticles coated with protein having luminol bonded thereto, causing the phagocytic cells to engulf the particles thus activating the cells' biochemical mechanism which reacts with the luminol generating light which is mea-sured on a luminometer.
2. The method of claim 1 wherein the particles are polymeric beads having diameters of about 2 microns to about 9 microns.
3. The method of claim 2 wherein the beads are polyacrylamide.
4. The method of claim 1 wherein the particles are zymosan particles.
5. A phagocytic composition comprising poly-acrylamide particles having a diameter of about 2 microns to about 9 microns coated with a layer of serum protein having a layer of luminol bonded thereto.
6. The composition of claim 5 in lyophilized form.
7. A phagocytic composition comprising zymosan particles coated with a layer of serum protein and lumi-nol.
8. The composition of claim 8 in lyophilized form.
9. A method of making a phagocytic reagent com-prising coating particulate material about 2 microns to about 9 microns in diameter with a layer of protein and luminol, and lyophilizing the coated particles to a stable, homogeneous product.
10. The method of claim 9 wherein the protein layer is applied first and the luminol applied thereto.
11. The method of claim 9 wherein the luminol is admixed with the protein prior to application to the par-ticulate material.
12. The method of claim 9 wherein the particulate material is polyacrylamide or zymosan.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44970982A | 1982-12-14 | 1982-12-14 | |
| US449,709 | 1989-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1210328A true CA1210328A (en) | 1986-08-26 |
Family
ID=23785187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000441805A Expired CA1210328A (en) | 1982-12-14 | 1983-11-23 | Method and composition for the evaluation of phagocytic response |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS59132361A (en) |
| AU (1) | AU2217783A (en) |
| CA (1) | CA1210328A (en) |
| DE (1) | DE3344607A1 (en) |
| FI (1) | FI834603A (en) |
| FR (1) | FR2537723A1 (en) |
| GB (1) | GB2131948B (en) |
| IT (1) | IT1169988B (en) |
| SE (1) | SE8306808L (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6036962A (en) * | 1983-08-09 | 1985-02-26 | Toray Ind Inc | Fine particle for biological inspection |
| FI853606A0 (en) * | 1984-09-21 | 1985-09-16 | Johnathan L Kiel | MICROLUMINISCENT ANALYSSYSTEM |
| CA2097952C (en) * | 1993-06-08 | 2006-03-14 | Alex D. Romaschin | Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence |
| US6203997B1 (en) | 1994-06-08 | 2001-03-20 | Sepsis, Inc. | Quantitation of analytes in whole blood |
| US5804370A (en) * | 1994-06-08 | 1998-09-08 | Critichem Medical Products Limited | Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence |
| US6159683A (en) * | 1997-12-16 | 2000-12-12 | Spectral Diagnostics, Inc. | Method of determining stage of sepsis |
| GB9910975D0 (en) | 1999-05-13 | 1999-07-14 | Univ Strathclyde | Rapid dehydration of proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3327119A (en) * | 1964-03-26 | 1967-06-20 | Ibm | Method and apparatus for detecting cancer cells |
| US4146604A (en) * | 1973-05-31 | 1979-03-27 | Block Engineering, Inc. | Differential counting of leukocytes and other cells |
| DE2732272C2 (en) * | 1977-07-16 | 1979-07-05 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, 6900 Heidelberg | Method and device for fluorescence analysis of colored particles, in particular biological cells |
| US4336029A (en) * | 1980-08-15 | 1982-06-22 | Ortho Diagnostic Systems Inc. | Method and reagents for quantitative determination of reticulocytes and platelets in whole blood |
-
1983
- 1983-11-23 CA CA000441805A patent/CA1210328A/en not_active Expired
- 1983-12-05 GB GB08332404A patent/GB2131948B/en not_active Expired
- 1983-12-07 AU AU22177/83A patent/AU2217783A/en not_active Abandoned
- 1983-12-08 FR FR8319657A patent/FR2537723A1/en not_active Withdrawn
- 1983-12-09 DE DE19833344607 patent/DE3344607A1/en not_active Withdrawn
- 1983-12-09 SE SE8306808A patent/SE8306808L/en not_active Application Discontinuation
- 1983-12-12 JP JP58234123A patent/JPS59132361A/en active Pending
- 1983-12-14 IT IT24159/83A patent/IT1169988B/en active
- 1983-12-14 FI FI834603A patent/FI834603A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE3344607A1 (en) | 1984-06-14 |
| IT1169988B (en) | 1987-06-03 |
| GB8332404D0 (en) | 1984-01-11 |
| GB2131948A (en) | 1984-06-27 |
| SE8306808D0 (en) | 1983-12-09 |
| JPS59132361A (en) | 1984-07-30 |
| FI834603A0 (en) | 1983-12-14 |
| IT8324159A0 (en) | 1983-12-14 |
| AU2217783A (en) | 1984-06-21 |
| FI834603A (en) | 1984-06-15 |
| FR2537723A1 (en) | 1984-06-15 |
| SE8306808L (en) | 1984-06-15 |
| IT8324159A1 (en) | 1985-06-14 |
| GB2131948B (en) | 1986-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5001048A (en) | Electrical biosensor containing a biological receptor immobilized and stabilized in a protein film | |
| US5192507A (en) | Receptor-based biosensors | |
| US4483929A (en) | Liposomes with glycolipid-linked antibodies | |
| Singer et al. | The latex fixation test: I. Application to the serologic diagnosis of rheumatoid arthritis | |
| Bass et al. | Subpopulations of neutrophils with increased oxidative product formation in blood of patients with infection. | |
| Insel et al. | Relationships between membrane cholesterol, α-adrenergic receptors, and platelet function | |
| US3915805A (en) | Quantitative detection of endotoxin in biological fluids | |
| GB1561042A (en) | Method for detecting and separating antigens and antibodies in blood or other samples | |
| US4130634A (en) | Method for detecting and quantifying antigens | |
| CN109387625B (en) | Binding assays for diagnosing heparin-induced thrombocytopenia | |
| Weening et al. | Defective initiation of the metabolic stimulation in phagocytizing granulocytes: a new congenital defect | |
| US4410660A (en) | Binding assay for the detection of mycobacteria | |
| JPS6367864B2 (en) | ||
| CA1210328A (en) | Method and composition for the evaluation of phagocytic response | |
| IE903900A1 (en) | Chemiluminescence assay of inflammation | |
| US5476797A (en) | Process and apparatus for detecting sensitized leukocyte or antigen | |
| US4402819A (en) | Antibody-selective membrane electrodes | |
| JP2002518062A (en) | Method for measuring antibiotics containing β-lactam rings in biological fluids | |
| FI68468B (en) | DIRECTIVE AGRICULTURAL TEST FOR ANTIGENERS IN CROPPING | |
| Hamaguchi et al. | Enzyme‐Linked Sandwich Immunoassay of Macromolecular Antigens Using the Rabbit Antibody‐Coupled Glass Rod as a Solid Phase | |
| CA1168580A (en) | Immunological reagent for the detection of tubes of the rheumatoid factor in a biological specimen and process for preparing this novel reagent | |
| Cowan et al. | Platelet adherence to collagen: role of plasma, ADP, and divalent cations | |
| CA1334825C (en) | Solid phase indicator red blood cells and method | |
| EP0215099A1 (en) | Method for the early diagnosis of bordetella diseases and kit therefor | |
| JPS59108959A (en) | Method of determining histamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |